Obesity is thought to increase renal hyperfiltration, thereby increasing albuminuria and the progression of renal disease. The effect of pharmacologically mediated weight loss on renal outcomes is not well-described.
Background: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or...
Eisai announced positive topline results from the CAMELLIA-TIMI 61 cardiovascular outcome trial, a 12,000 patient study of Belviq (lorcaserin HCl)...
Eisai Co., Ltd. has announced that results from the Cardiovascular Outcomes Trial (CAMELLIA-TIMI 61) in patients treated with lorcaserin hydrochloride...
Arena Pharmaceuticals, Inc. announced that it has amended its Belviq (lorcaserin HCl) marketing and supply agreement with Eisai Co., Ltd....
Take a look at a series of drug options and their effectiveness as treatments for obesity, as well as their ability to tackle diabetes and cardiovascular disease.
Areas covered: Herein, the authors review the most commonly used FDA approved medications for the treatment of obesity, describing their mechanism of action, and the efficacy and safety of the medications as seen in...
Eisai and Arena Pharmaceuticals have announced that the FDA has accepted for filing the New Drug Application for an extended...
Purpose of review: Obesity is a major risk factor for the development of de novo chronic kidney disease (CKD). However, once kidney disease is acquired, obesity is paradoxically linked with greater survival, especially in those with advanced CKD.
The FDA has requested that Eisai Co. Ltd. voluntarily withdraw the obesity pills Belviq and Belviq XR (lorcaserin) from the...